Health Canada approves AbbVie’s Skyrizi for pediatric plaque psoriasis
ABBV•Health Canada approved AbbVie’s Skyrizi for moderate-to-severe plaque psoriasis in children ages 6 to under 18 who are candidates for systemic therapy or phototherapy.
1. Approval details
Health Canada approved Skyrizi for moderate-to-severe plaque psoriasis in children ages 6 to under 18. Eligible patients must be candidates for systemic therapy or phototherapy.
